215 related articles for article (PubMed ID: 27929754)
1. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy.
Paolini F; Curzio G; Cordeiro MN; Massa S; Mariani L; Pimpinelli F; de Freitas AC; Franconi R; Venuti A
Hum Vaccin Immunother; 2017 Feb; 13(2):291-297. PubMed ID: 27929754
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effects of genetic vaccines against HPV major oncogenes.
Cordeiro MN; Paolini F; Massa S; Curzio G; Illiano E; Duarte Silva AJ; Franconi R; Bissa M; Morghen Cde G; de Freitas AC; Venuti A
Hum Vaccin Immunother; 2015; 11(1):45-52. PubMed ID: 25483514
[TBL] [Abstract][Full Text] [Related]
3. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.
Liao SJ; Deng DR; Zeng D; Zhang L; Hu XJ; Zhang WN; Li L; Jiang XF; Wang CY; Zhou JF; Wang SX; Zhang HW; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):735-742. PubMed ID: 24142729
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
[TBL] [Abstract][Full Text] [Related]
5. Development of multiepitope therapeutic vaccines against the most prevalent high-risk human papillomaviruses.
Panahi HA; Bolhassani A; Javadi G; Noormohammadi Z; Agi E
Immunotherapy; 2020 May; 12(7):459-479. PubMed ID: 32316826
[No Abstract] [Full Text] [Related]
6. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
7. hrHPV E5 oncoprotein: immune evasion and related immunotherapies.
de Freitas AC; de Oliveira THA; Barros MR; Venuti A
J Exp Clin Cancer Res; 2017 May; 36(1):71. PubMed ID: 28545552
[TBL] [Abstract][Full Text] [Related]
8. Current research into novel therapeutic vaccines against cervical cancer.
Cordeiro MN; De Lima RCP; Paolini F; Melo ARDS; Campos APF; Venuti A; De Freitas AC
Expert Rev Anticancer Ther; 2018 Apr; 18(4):365-376. PubMed ID: 29475377
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene.
Gao J; Fan L; Ma W; Xiao H
Microbiol Immunol; 2016 Sep; 60(9):626-33. PubMed ID: 27515281
[TBL] [Abstract][Full Text] [Related]
10. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
11. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
12. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
13. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
14. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
15. Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.
Ma Y; Yang A; Peng S; Qiu J; Farmer E; Hung CF; Wu TC
Vaccine; 2017 Jul; 35(31):3850-3858. PubMed ID: 28599791
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus does not have a causal role in colorectal carcinogenesis.
Lorenzon L; Mazzetta F; Pilozzi E; Uggeri G; Torrisi MR; Ferri M; Ziparo V; French D
World J Gastroenterol; 2015 Jan; 21(1):342-50. PubMed ID: 25574110
[TBL] [Abstract][Full Text] [Related]
17. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 E5 protein as a therapeutic target.
Kim SW; Yang JS
Yonsei Med J; 2006 Feb; 47(1):1-14. PubMed ID: 16502480
[TBL] [Abstract][Full Text] [Related]
19. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
20. Identification of immunotherapeutic epitope of E5 protein of human papillomavirus-16: An in silico approach.
Kumar A; Yadav IS; Hussain S; Das BC; Bharadwaj M
Biologicals; 2015 Sep; 43(5):344-8. PubMed ID: 26212000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
